{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:32:02Z","timestamp":1786120322977,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1097\/mph.0b013e31821f0eaf","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T04:21:40Z","timestamp":1311654100000},"page":"e226-e230","source":"Crossref","is-referenced-by-count":26,"title":["Survival and Long-term Outcomes in Children With Hepatoblastoma Treated With Continuous Infusion of Cisplatin and Doxorubicin"],"prefix":"10.1097","volume":"33","author":[{"given":"Ponni","family":"Sivaprakasam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha A.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark L.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Capra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210227","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1056\/NEJMoa0810613","article-title":"Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma.","volume":"361","author":"Perilongo","year":"2009","journal-title":"N Engl J Med"},{"key":"R2-20-20210227","doi-asserted-by":"crossref","first-page":"5623","DOI":"10.1002\/cncr.24668","article-title":"Hepatoblastoma, cisplatin, and ototoxicity: good news on deaf ears.","volume":"115","author":"Sullivan","year":"2009","journal-title":"Cancer"},{"key":"R3-20-20210227","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1200\/JCO.2000.18.22.3819","article-title":"Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approachresults of the first prospective study of the International Society of Pediatric Oncology.","volume":"18","author":"Pritchard","year":"2000","journal-title":"J Clin Oncol"},{"key":"R4-20-20210227","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1200\/JCO.2000.18.14.2665","article-title":"Randomized comparison of cisplatinvincristinefluorouracil and cisplatincontinuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Childrens Cancer Group and the Pediatric Oncology Group.","volume":"18","author":"Ortega","year":"2000","journal-title":"J Clin Oncol"},{"key":"R5-20-20210227","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/mpo.2950190415","article-title":"Cisplatin ototoxicity in children: a practical grading system.","volume":"19","author":"Brock","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"R6-20-20210227","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"R7-20-20210227","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/01.mph.0000199586.98926.8e","article-title":"Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors.","volume":"28","author":"Gupta","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"R10-20-20210227","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"R11-20-20210227","first-page":"103","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration.","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"R12-20-20210227","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1200\/JCO.2002.20.6.1677","article-title":"Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.","volume":"20","author":"Lipshultz","year":"2002","journal-title":"J Clin Oncol"},{"key":"R14-20-20210227","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1002\/1097-0142(19931115)72:10<3120::AID-CNCR2820721038>3.0.CO;2-Q","article-title":"Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: the Memorial Sloan-Kettering-New York-II protocol.","volume":"72","author":"Steinherz","year":"1993","journal-title":"Cancer"},{"key":"R15-20-20210227","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer"},{"key":"R16-20-20210227","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development.","volume":"23","author":"Knight","year":"2005","journal-title":"J Clin Oncol"},{"key":"R17-20-20210227","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose.","volume":"40","author":"Li","year":"2004","journal-title":"Eur J Cancer"},{"key":"R18-20-20210227","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2006.08.9599","article-title":"Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors.","volume":"25","author":"Oldenburg","year":"2007","journal-title":"J Clin Oncol"},{"key":"R19-20-20210227","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.","volume":"41","author":"Ross","year":"2009","journal-title":"Nat Genet"},{"key":"R20-20-20210227","first-page":"19","article-title":"Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.","volume":"66","author":"Reddel","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"R21-20-20210227","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/1097-0142(19840215)53:4<837::AID-CNCR2820530403>3.0.CO;2-L","article-title":"Cis-diamminedichloroplatinum (II) by 5-day continuous infusion: a new dose schedule with minimal toxicity.","volume":"53","author":"Salem","year":"1984","journal-title":"Cancer"},{"key":"R22-20-20210227","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pbc.20673","article-title":"Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.","volume":"47","author":"Lanvers-Kaminsky","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R23-20-20210227","doi-asserted-by":"crossref","first-page":"5828","DOI":"10.1002\/cncr.24667","article-title":"Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Childrens Oncology Group.","volume":"115","author":"Katzenstein","year":"2009","journal-title":"Cancer"},{"key":"R24-20-20210227","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1200\/JCO.2007.14.3974","article-title":"Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma.","volume":"26","author":"Fouladi","year":"2008","journal-title":"J Clin Oncol"},{"key":"R26-20-20210227","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1084713807304668","article-title":"Unilateral and mild bilateral hearing loss in children: past and current perspectives.","volume":"12","author":"Tharpe","year":"2008","journal-title":"Trends Amplif"},{"key":"R28-20-20210227","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1542\/peds.2009-1597","article-title":"Auditory late effects of childhood cancer therapy: a report from the Childrens Oncology Group.","volume":"125","author":"Grewal","year":"2010","journal-title":"Pediatrics"},{"key":"R29-20-20210227","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.2009.26.7872","article-title":"Critical need for international consensus on ototoxicity assessment criteria.","volume":"28","author":"Neuwelt","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0b013e31821f0eaf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:21:35Z","timestamp":1786047695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00043426-201108000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0b013e31821f0eaf","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}